Abstract:Red blood cell (RBC) transfusion has become one of the most commonly utilized life-saving therapies in medicine with approximately 12–16 million units transfused in the US per year [1,2]. Since storage solutions were developed 100 years ago, they have been modified to allow for increased storage duration, primarily to increase availability, especially in remote areas, such as during combat operations [3]. Currently in the US and Europe, RBCs can be stored up to 42–56 days based upon at least 75% of radiochromium-labeled cells remaining in the circulation at 24 h after infusion and hemolysis less than 1% [4,5]. As RBCs are stored over time, the metabolic and biochemical changes that occur have been coined ‘the storage lesion.’ To further improve the availability of RBCs, it is standard for blood distributors to transfer RBCs that are close to expiration at community hospitals to medical centers where utilization rates are higher, and for hospital blood banks to issue the ‘first-in, first-out’ inventory to reduce RBC outdating and waste [2,6]. A consequence of these policies focused on inventory management is that patients with increased severity of illness are transfused RBCs of increased storage duration compared to less acutely ill patients. It is important to recognize that as storage duration for RBC units has increased for logistical purposes, there has not been a commensurate evaluation of clinical efficacy or safety. As a result of the preferential allocation of older RBCs to sicker patients, there has been concern regarding the quality of RBCs after prolonged storage related to both efficacy and safety. This has led to a significant amount of research into the clinical relevance of the storage lesion with laboratory, preclinical, and clinical studies [4,7–9]. The results of these studies suggested biologic plausibility that the RBC storage lesion was potentially able to affect outcomes, especially in critically ill populations. These studies though are limited due to potential bias and higher-quality studies were needed to more accurately determine if RBC storage age affects outcomes. Consequently, a few randomized controlled trials (RCTs) have been completed, and a few are still underway. Dissecting out what each of these studies may mean for patients who are transfused RBCs based upon the population studied and their design is controversial. 2. ‘Storage lesion’

Ph-Resistant Titania Hybrid Organic–inorganic Coating for Stir Bar Sorptive Extraction of Drugs of Abuse in Urine Samples Followed by High Performance Liquid Chromatography–ultraviolet Visible Detection

Effect of growth hormone on the glomerular filtration response to a protein meal.

Bile acid composition in patients with and without symptoms of postoperative refulx gastritis.

Simultaneous determination of 11 monohydroxylated PAHs in human urine by stir bar sorptive extraction and liquid chromatography/tandem mass spectrometry.

Carboxyl hybrid monolithic column in-tube solid-phase microextraction coupled with UPLC-QTRAP MS/MS for the determination of amphetamine-type stimulants

Determination of Illicit Drugs in Aqueous Environmental Samples by Online Solid-Phase Extraction Coupled to Liquid Chromatography–tandem Mass Spectrometry

Portable Kit for Identification and Detection of Drugs in Human Urine Using Surface-Enhanced Raman Spectroscopy.

Rapid On-Site Detection of Illicit Drugs in Urine Using C18 Pipette-Tip Based Solid-Phase Extraction Coupled with a Miniaturized Mass Spectrometer

Hydroxyl-containing porous organic framework coated stir bar sorption extraction combined with high performance liquid chromatography-diode array detector for analysis of triazole fungicides in grape and cabbage samples

Magnetic Solid-Phase Extraction Based on Polydopamine-Coated Magnetic Nanoparticles for Rapid and Sensitive Analysis of Eleven Illicit Drugs and Metabolites in Wastewater with the Aid of UHPLC-MS/MS.

Polyoxometalate-Based Frameworks as Adsorbents for Drug of Abuse Extraction from Hair Samples

Red blood cell storage age – what we know from clinical trials

Integrated Sensing Platform Validated for the Efficient and On-Site Screening of Amine-Containing Illicit Drugs

Preparation and application of nano petal-shaped covalent organic frameworks modified polystyrene-divinylbenzene- glycidylmethacrylate microspheres for the extraction of illicit drugs from wastewater

Ultrasensitive and rapid detection for multiple dopings in saliva and urine using surface-enhanced Raman spectroscopy

Fabrication of carboxyl functionalized microporous organic network coated stir bar for efficient extraction and analysis of phenylurea herbicides in food and water samples

Ultrasound-assisted Dispersive Liquid-Liquid Microextraction for the Determination of Seven Recreational Drugs in Human Whole Blood Using Gas Chromatography–mass Spectrometry

Automatic analytical approach for the determination of 12 illicit drugs and nicotine metabolites in wastewater using on-line SPE-UHPLC-MS/MS

Hybrid silica material as a mixed-mode sorbent for solid-phase extraction of hydrophobic and hydrophilic illegal additives from food samples

Uniform solid-phase extraction procedure for toxicological drug screening in serum and urine by HPLC with photodiode-array detection

Investigating the drug abuse in hair samples with electrospun nanostructure PEDOT-CNT along with EA-IT-SPME